Location
Suwanee, GA
Start Date
17-4-2026 12:00 PM
End Date
17-4-2026 1:00 PM
Description
Women who experience recurrent urinary tract infections (rUTIs), defined as more than three infections per year, often face significant reduction in their quality of life, including travel and employment. Additionally, there is concern about the long-term effects of prolonged and repeated use of antibiotics, which are currently the standard for prophylaxis and treatment. Overuse often results in resistance. Multiple countries currently offer, or are in the process of developing, vaccines that can prevent rUTI. Uromune MV140 from Immunotek is one such vaccine. This study was conducted as a literature review evaluating the safety, efficacy, mechanism of action, and clinical use of Uromune MV140 in reducing recurrent urinary tract infections. A comprehensive search was performed on randomized controlled trials, multicenter cohort studies, observational studies, systematic reviews, and phase III clinical trials. Uromune MV140 is an inactivated vaccine that contains killed bacteria from the four most common uropathogens, such as Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, and Enterococcus faecalis. Uromune MV140 is approved in other countries but not in the U.S.A. However, studies have shown that Uromune MV140 can significantly decrease the number of urinary tract infections that patients with rUTI experience each year. Mechanistically, Uromune MV140 elicits Th1 and Th17 T cell response along with IgA, IgG and IgM antibodies to combat rUTIs with minimal side effects that were not clinically limiting. In summary, Uromune MV140 shows promising results in reducing infection frequency with minimal adverse effects. However, further large-scale research, particularly in the United States, is needed to determine its long-term safety, efficacy, and accessibility for the American population.
Embargo Period
6-1-2026
Included in
Breaking the Cycle: Uromune MV140 in the Prevention of Recurrent Urinary Tract Infections (rUTIs)
Suwanee, GA
Women who experience recurrent urinary tract infections (rUTIs), defined as more than three infections per year, often face significant reduction in their quality of life, including travel and employment. Additionally, there is concern about the long-term effects of prolonged and repeated use of antibiotics, which are currently the standard for prophylaxis and treatment. Overuse often results in resistance. Multiple countries currently offer, or are in the process of developing, vaccines that can prevent rUTI. Uromune MV140 from Immunotek is one such vaccine. This study was conducted as a literature review evaluating the safety, efficacy, mechanism of action, and clinical use of Uromune MV140 in reducing recurrent urinary tract infections. A comprehensive search was performed on randomized controlled trials, multicenter cohort studies, observational studies, systematic reviews, and phase III clinical trials. Uromune MV140 is an inactivated vaccine that contains killed bacteria from the four most common uropathogens, such as Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, and Enterococcus faecalis. Uromune MV140 is approved in other countries but not in the U.S.A. However, studies have shown that Uromune MV140 can significantly decrease the number of urinary tract infections that patients with rUTI experience each year. Mechanistically, Uromune MV140 elicits Th1 and Th17 T cell response along with IgA, IgG and IgM antibodies to combat rUTIs with minimal side effects that were not clinically limiting. In summary, Uromune MV140 shows promising results in reducing infection frequency with minimal adverse effects. However, further large-scale research, particularly in the United States, is needed to determine its long-term safety, efficacy, and accessibility for the American population.
Comments
Awarded "Best Original Research" at PCOM Georgia Research Day 2026.